Shigella Infections (Shigellosis) - Pipeline Review, H1 2016
Summary
Global Markets Direct’s, ‘Shigella Infections (Shigellosis) - Pipeline Review, H1 2016’, provides an overview of the Shigella Infections (Shigellosis) pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Shigella Infections (Shigellosis), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Shigella Infections (Shigellosis) and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Shigella Infections (Shigellosis)
- The report reviews pipeline therapeutics for Shigella Infections (Shigellosis) by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Shigella Infections (Shigellosis) therapeutics and enlists all their major and minor projects
- The report assesses Shigella Infections (Shigellosis) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Shigella Infections (Shigellosis)
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Shigella Infections (Shigellosis)
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Shigella Infections (Shigellosis) pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table Of Contents
Table of Contents
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Shigella Infections (Shigellosis) Overview 7
Therapeutics Development 8
Pipeline Products for Shigella Infections (Shigellosis) – Overview 8
Pipeline Products for Shigella Infections (Shigellosis) – Comparative Analysis 9
Shigella Infections (Shigellosis) – Therapeutics under Development by Companies 10
Shigella Infections (Shigellosis) – Therapeutics under Investigation by Universities/Institutes 11
Shigella Infections (Shigellosis) – Pipeline Products Glance 12
Clinical Stage Products 12
Early Stage Products 13
Shigella Infections (Shigellosis) – Products under Development by Companies 14
Shigella Infections (Shigellosis) – Products under Investigation by Universities/Institutes 15
Shigella Infections (Shigellosis) – Companies Involved in Therapeutics Development 16
Anacor Pharmaceuticals, Inc. 16
GlaxoSmithKline Plc 17
Microbiotix, Inc. 18
Protein Potential, LLC 19
Visterra, Inc. 20
Shigella Infections (Shigellosis) – Therapeutics Assessment 21
Assessment by Monotherapy Products 21
Assessment by Combination Products 22
Assessment by Target 23
Assessment by Mechanism of Action 25
Assessment by Route of Administration 26
Assessment by Molecule Type 28
Drug Profiles 30
(shigella + typhoid) vaccine - Drug Profile 30
Product Description 30
Mechanism of Action 30
R&D Progress 30
1790GAHB - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
GVXNSD-133 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
INX-201 - Drug Profile 33
Product Description 33
Mechanism of Action 33
R&D Progress 33
KKL-35 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
SC-599 - Drug Profile 35
Product Description 35
Mechanism of Action 35
R&D Progress 35
SE-1 - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
shigella vaccine - Drug Profile 37
Product Description 37
Mechanism of Action 37
R&D Progress 37
shigella vaccine - Drug Profile 38
Product Description 38
Mechanism of Action 38
R&D Progress 38
shigella vaccine - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
shigella vaccine 1 - Drug Profile 40
Product Description 40
Mechanism of Action 40
R&D Progress 40
Shigetec - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
Small Molecule for Shigellosis - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
Small Molecule to Activate IL-10 for Bacterial Infections and Crohn's Disease - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
VIS-GMN - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Shigella Infections (Shigellosis) – Recent Pipeline Updates 45
Shigella Infections (Shigellosis) - Dormant Projects 46
Shigella Infections (Shigellosis) – Discontinued Products 47
Shigella Infections (Shigellosis) – Product Development Milestones 48
Featured News & Press Releases 48
Jul 29, 2013: GlycoVaxyn Secures CHF 5.1 Million Strategic Translation Award From the Wellcome Trust to Finance Clinical Development of Shigella Vaccine 48
Feb 20, 2013: NIH-Funded Researchers Begin Trial of Shigella Vaccine Candidates 48
Jan 27, 2012: IVI Granted Two U.S. Patents On Dysentery Vaccine Inventions 49
Oct 08, 2010: GlycoVaxyn Phase I Clinical Study Shows Positive Data With Shigella Dysenteriae Vaccine Candidate Against Severe Diarrheal Disease 50
Feb 23, 2010: GlycoVaxyn Initiates Phase I Clinical Study with Bioconjugate Vaccine 51
Feb 15, 2007: IVI Scientists Develop New Laboratory Animal Model For Shigella 51
Appendix 52
Methodology 52
Coverage 52
Secondary Research 52
Primary Research 52
Expert Panel Validation 52
Contact Us 52
Disclaimer 53
List Of Tables
List of Tables
Number of Products under Development for Shigella Infections (Shigellosis), H1 2016 8
Number of Products under Development for Shigella Infections (Shigellosis) – Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Development, H1 2016 13
Products under Development by Companies, H1 2016 14
Products under Investigation by Universities/Institutes, H1 2016 15
Shigella Infections (Shigellosis) – Pipeline by Anacor Pharmaceuticals, Inc., H1 2016 16
Shigella Infections (Shigellosis) – Pipeline by GlaxoSmithKline Plc, H1 2016 17
Shigella Infections (Shigellosis) – Pipeline by Microbiotix, Inc., H1 2016 18
Shigella Infections (Shigellosis) – Pipeline by Protein Potential, LLC, H1 2016 19
Shigella Infections (Shigellosis) – Pipeline by Visterra, Inc., H1 2016 20
Assessment by Monotherapy Products, H1 2016 21
Assessment by Combination Products, H1 2016 22
Number of Products by Stage and Target, H1 2016 24
Number of Products by Stage and Mechanism of Action, H1 2016 25
Number of Products by Stage and Route of Administration, H1 2016 27
Number of Products by Stage and Molecule Type, H1 2016 29
Shigella Infections (Shigellosis) Therapeutics – Recent Pipeline Updates, H1 2016 45
Shigella Infections (Shigellosis) – Dormant Projects, H1 2016 46
Shigella Infections (Shigellosis) – Discontinued Products, H1 2016 47
Lisst Of Figures
List of Figures
Number of Products under Development for Shigella Infections (Shigellosis), H1 2016 8
Number of Products under Development for Shigella Infections (Shigellosis) – Comparative Analysis, H1 2016 9
Number of Products under Development by Companies, H1 2016 10
Number of Products under Investigation by Universities/Institutes, H1 2016 11
Comparative Analysis by Clinical Stage Development, H1 2016 12
Comparative Analysis by Early Stage Products, H1 2016 13
Assessment by Monotherapy Products, H1 2016 21
Number of Products by Targets, H1 2016 23
Number of Products by Stage and Top 10 Targets, H1 2016 23
Number of Products by Routes of Administration, H1 2016 26
Number of Products by Stage and Routes of Administration, H1 2016 26
Number of Products by Molecule Types, H1 2016 28
Number of Products by Stage and Molecule Types, H1 2016 28
